CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $2.07B, above the global median of $1.15B
- FinancialsAltman Z-Score 4.69: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.93%Above 5Y avg (1.89%)
Annual Rate
CNY 0.28Paid annual
Payout Ratio
47.4%Sustainable
Payback Period
47.2 yr
Last Ex-Dividend
Jul 9, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
13.96BCNY2.07B · vs all stocks (USD)
Trailing P/E
17.99xRevenue (TTM)
8.82BCNY1.31B · vs all stocks (USD)
Profit Margin
8.52%Beta
0.3190xvs all stocks
52-Week Change
-10.54%vs all stocks
Market Capitalization
13.96BCNY2.07B · vs all stocks (USD)
Enterprise Value
10.89BCNY1.62B · vs all stocks (USD)
Trailing P/E
17.99xForward P/E
12.31xPrice to Sales (TTM)
1.53xPrice to Book (MRQ)
1.18xEnterprise to Revenue
1.24xEnterprise to EBITDA
7.52xGross Margin
35.06%Profit Margin
8.52%Operating Margin
15.07%Return on Assets (TTM)
3.29%Return on Equity (TTM)
5.60%Revenue (TTM)
8.82BCNY1.31B · vs all stocks (USD)
Revenue per Share (TTM)
9.22CNYUpdated Aug 20, 2026Quarterly Revenue Growth
-2.90%Gross Profit (TTM)
2.69BCNY398.83M · vs all stocks (USD)
EBITDA (TTM)
1.19BCNY177.38M · vs all stocks (USD)
Net Income (TTM)
751.31MCNY111.58M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-29.80%Operating Cash Flow (TTM)
1.68BCNY249.64M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
1.10BCNY162.95M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.2800CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
1.93%vs all stocks
5-Year Average Dividend Yield
1.89%vs all stocks
Payout Ratio
47.44%Minority Interest (Equity)
145.69MCNYFY2025 · Dec 31, 2025Revenue
8.88BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
5.80BCNYFY2025 · Dec 31, 2025Gross Profit
3.08BCNYFY2025 · Dec 31, 2025Operating Income
1.08BCNY160.27M · vs all stocks (USD)
Pre-tax Income
951.73MCNYFY2025 · Dec 31, 2025Income Tax Expense
191.49MCNYFY2025 · Dec 31, 2025Net Income
760.24MCNYFY2025 · Dec 31, 2025EBIT
976.55MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.96BCNYFY2025 · Dec 31, 2025Research & Development
579.88MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
990.95MCNYFY2025 · Dec 31, 2025Other Operating Expenses
99.40MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
30.14MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
24.82MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.9100CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.9100CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
959.76MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
959.76MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
760.24MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
113.14MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
890.85MCNYFY2025 · Dec 31, 2025Free Cash Flow
446.25MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
3.17BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
760.24MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-45.64MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
144.04MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
32.21MCNYFY2025 · Dec 31, 2025Capital Expenditures
-444.61MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.26BCNYFY2025 · Dec 31, 2025Sale of Investments
1.27BCNYFY2025 · Dec 31, 2025Other Investing Activity
65.57MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-371.95MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
695.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-577.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-376.69MCNYFY2025 · Dec 31, 2025Other Financing Charges
-144.17MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-402.86MCNYFY2025 · Dec 31, 2025Shares Outstanding
961.64MSharesUpdated Aug 20, 2026Float Shares
569.50MSharesUpdated Aug 20, 2026% Held by Insiders
40.91%vs all stocks
% Held by Institutions
4.05%vs all stocks
Total Cash (MRQ)
3.24BCNY481.14M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.42CNYUpdated Aug 20, 2026Total Debt (MRQ)
957.35MCNY142.19M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0842xCurrent Ratio (MRQ)
3.39xBook Value per Share (MRQ)
11.86CNYUpdated Aug 20, 2026Total Assets
14.09BCNY2.09B · vs all stocks (USD)
Total Current Assets
7.21BCNYFY2025 · Dec 31, 2025Total Liabilities
3.00BCNYFY2025 · Dec 31, 2025Total Non-current Assets
6.88BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
561.82MCNYFY2025 · Dec 31, 2025Total Current Liabilities
2.44BCNYFY2025 · Dec 31, 2025Cash
3.17BCNYFY2025 · Dec 31, 2025Cash Equivalents
1.84MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
3.17BCNYFY2025 · Dec 31, 2025Other Short-term Investments
250.32MCNYFY2025 · Dec 31, 2025Accounts Receivable
1.47BCNYFY2025 · Dec 31, 2025Inventory
1.85BCNYFY2025 · Dec 31, 2025Accounts Payable
1.12BCNYFY2025 · Dec 31, 2025Short-term Debt
508.80MCNYFY2025 · Dec 31, 2025Other Current Liabilities
2.05MCNYFY2025 · Dec 31, 2025Long-term Debt
357.61MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
73.70MCNYFY2025 · Dec 31, 2025Common Stock (Book)
961.64MCNYFY2025 · Dec 31, 2025Retained Earnings
6.36BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
11.09BCNY1.65B · vs all stocks (USD)
Treasury Stock
125.49MCNYFY2025 · Dec 31, 202552-Week Low
10.94CNYUpdated Aug 20, 202652-Week High
18.58CNYUpdated Aug 20, 202652-Week Change
-10.54%vs all stocks
Beta
0.3190xvs all stocks
50-Day MA
12.16CNYUpdated Aug 20, 2026200-Day MA
14.10CNYUpdated Aug 20, 2026Avg 10-Day Volume
45.43MSharesUpdated Aug 20, 2026Avg 30-Day Volume
27.92MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.7800CNYUpdated Aug 20, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.69: safe zoneNotable
Altman Z-Score: 4.69
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $2.07B, above the global median of $1.15BNotable
Market cap (USD): 2,073,781,808.908Global Median: 1,146,734,693.424
Revenue is $1.31B, above the global median of $520.53MNotable
Revenue (USD): 1,309,363,878.42Global Median: 520,528,949.311
Levered free cash flow is $162.95M, above the global median of $16.24MNotable
Levered free cash flow (USD): 162,945,422.044Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Mabwell (Shanghai) Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Monte Rosa Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Weigao Blood Purification Products Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kalbe Farma Tbk. PT
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ab&B Bio-Tech Co., Ltd. (JS)
Tier 1ProductionApproval-Gated PipelineRule
Verano Holdings Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Aurinia Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
GemPharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Anke Biotechnology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Hubei Jumpcan Pharmaceutical Co., Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
CIE Automotive India Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Manhattan Associates Inc.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities